Hangzhou Just Biotherapeutics has this week announced the close of a $35m series B funding round led by China-based investment firm Hillhouse Capital.

The round was also backed by returning investors Temasek, Lilly Asia Ventures, ARCH Venture Partners, Taikang and BOCGI Zheshang Capital. This brings Hangzhou Just Bio’s lifetime fundraising to over $120m to date.